Like Kinship Technologies Pvt. Ltd.

closed 5/20/2011 via PR Newswire

PRA International, acquired Kinship Technologies Pvt. Ltd.

synopsis: PRA International has acquired Kinship Technologies, a Chennai, India-based software developer and services company. Kinship's flagship product, EXACT, is a revolutionary system that allows users to quickly construct reusable programs for data extraction, data transformation, statistical reporting and electronic publishing.
buyer: PRA International (PRAH:$1,698.48)
PRA International conducts clinical trials across all therapeutic areas in more than 80 countries and provides services in all phases of clinical development through its 40 global offices. "
target: Kinship Technologies Pvt. Ltd.
Kinship Technologies is a leading, global provider of innovative high-quality software products and services that enhance, optimize and accelerate the drug development process from source to submission through integration, automation and effective application of advanced technology solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2020 via Company Press Release

Cytel Inc., acquired Laiya Consulting, Inc.

synopsis: Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. Laiya pioneered the delivery of trial design software using SaaS, which aligns with Cytel’s goal of making all of its design software available as a cloud-based service.
buyer parent: New Mountain Capital, LLC
buyer: Cytel Inc.
Cytel provides statistical software for clinical trials. Cytel provides an understanding of software tools that solve statistical problems and that meet the highest standards of reliability, technical documentation and customer support. "
target: Laiya Consulting, Inc.
Founded in 2010, Laiya Consulting has supported drug developers to drive success rates and maximize portfolio returns through the design and implementation of Bayesian adaptive trials, robust clinical strategies, and integrated software platforms.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/5/2016 via Company Press Release

Instem, acquired Notocord

synopsis: Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that it has acquired NOTOCORD. NOTOCORD provides software solutions for data acquisition and analysis in preclinical studies and is a recognized leader in cardiovascular, respiratory, electrophysiology and nervous system research areas.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
target: Notocord
Notocord, Inc. designs software and provides data acquisition, analysis, as well as reporting solutions. Their solutions are fit for preclinical R&D, including efficacy testing, early safety, regulatory safety pharmacology and toxicology studies.
price ($mm)
$2.25
rev ($mm)
$3
EBITDA ($mm)
EV / rev
2.0x
EV / EBITDA
closed 8/5/2009 via PR Newswire

OmniComm Systems, Inc., purchased EDC Assets from Logos Technologies

synopsis: OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials announced that the company has acquired the EDC assets of UK based, clinical software provider, Logos Technologies, Ltd.
buyer: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. "
seller: Logos Technologies
Logos Technologies is one of the early pioneers in providing world class solutions to pharmaceutical, contract research organisations and biotechnology companies with electronic data capture (EDC) and clinical management solutions needed to accelerate pharmaceutical research and development.
price ($mm)
$0.15
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2009 via PR Newswire

Oracle Corporation, acquired Conformia Software, Inc.

synopsis: Oracle announced that it has acquired the intellectual property assets of Conformia Software. Conformia's Product and Process Lifecycle Management (PPLM) software has unique capabilities which Oracle plans to integrate into their Agile PLM solution to offer an end-to-end solution for managing drug development, packaging and commercialization.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is the world's largest enterprise software company. The company is a leading provider of systems software, including database management, application development, and application server software. "
target: Conformia Software, Inc.
Conformia Software, Inc. offers product/process lifecycle management solutions for the pharmaceutical and life sciences, biotech, and other process manufacturing organizations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/19/2020 via Company Press Release

Capvis Equity, will acquire BSI Business Systems Integration

synopsis: Capvis AG, a leading private equity firm in Switzerland, will acquire a majority stake in BSI Business Systems Integration AG, a Swiss customer relationship management (CRM) software solution provider. BSI offers an omnichannel CRM and marketing automation platform that helps businesses to better support their customers.
buyer: Capvis Equity
Capvis is the leading private equity firm in Switzerland and a top player in German-speaking Europe. Capvis invests in well-positioned midsize firms with headquarters in Switzerland, Germany or Austria, typically as part of succession solutions and corporate spin-offs. "
target: BSI Business Systems Integration
Business Systems Integration (BSI) is a Swiss customer relationship management (CRM) software solution provider. BSI offers an omnichannel CRM and marketing automation platform that helps businesses to better support their customers. BIS also offers a clinical trial management software solution.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,061.43)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/18/2018 via PR Newswire

Genstar Capital LLC, acquired CRF Health

synopsis: Genstar Capital, a leading investor in healthcare technology and services companies, is pleased to announce the acquisition of CRF Health, a global provider of eCOA and eConsent solutions for the life sciences industry. CRF Health's eSource solutions improve trial engagement by making the patient the center of the clinical trial process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that has been actively investing in high quality companies for more than 25 years. Based in San Francisco, Genstar works in partnership with its management teams to transform its portfolio companies into industry-leading businesses. "
target parent: Vitruvian Partners LLP
target: CRF Health
CRF Health is the leading provider of patient-centered eSource technology solutions for the life sciences industry. CRF Health's TrialMax® platform consistently demonstrates the industry's highest data accuracy, patient and site compliance, and patient retention.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2017 via PR Newswire

Bracket Global, acquired mProve Health

synopsis: Bracket, a leading clinical trial technology and specialty services provider, announced the strategic acquisition of mProve Health Inc., a leading provider of mobile technologies for life science companies. mProve Health offers regulatory compliant mobile solutions for patient recruitment and electronic clinical outcome assessments.
buyer parent: Genstar Capital LLC
buyer: Bracket Global
Bracket is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. "
target: mProve Health
mProve Health is a leading provider of mobile technologies for life science companies, helping them connect better with patients. The company offers industry-grade, regulatory compliant mobile solutions for patient recruitment, patient engagement, and electronic clinical outcome assessments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/31/2017 via BusinessWire

Anju Software, acquired ClinPlus

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired the assets of ClinPlus, a division of DZS Software Solutions, Inc. ClinPlus has a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions with outstanding customer support. Anju was founded by a group of operating and investment professionals with deep software domain expertise. "
target parent: DZS Software Solutions, Inc.
target: ClinPlus
ClinPlus, a division of DZS Software Solutions, Inc., has a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/28/2017 via PR Newswire

Genstar Capital LLC, acquired Bracket Global

synopsis: Genstar Capital, a middle-market private equity firm focused on investments in targeted segments of the healthcare, financial services, software, and industrial technology industries, announced that it has acquired Bracket, a leading scientifically-driven clinical trial technology and specialty services provider, from Parthenon Capital Partners.
buyer: Genstar Capital LLC
Genstar Capital is a San Francisco-based private equity firm that invests in leading middle-market companies. For over 20 years, they have utilized their deep industry knowledge and extensive executive networks to create value at their companies. "
target parent: Parthenon Capital Partners
target: Bracket Global
Bracket is a specialty services provider dedicated to helping pharmaceutical sponsors and contract research organizations (CROs) achieve greater certainty and accurate outcomes in their clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/16/2016 via BNC Analysis

DrugDev, acquired SecureConsent

synopsis: DrugDev has acquired SecureConsent, a developer of mobile e-consent software. SecureConsent replaces the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
target: SecureConsent
The software products developed by Secure Consent replace the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/20/2011 via PR Newswire

PRA International, acquired Kinship Technologies Pvt. Ltd.

synopsis: PRA International has acquired Kinship Technologies, a Chennai, India-based software developer and services company. Kinship's flagship product, EXACT, is a revolutionary system that allows users to quickly construct reusable programs for data extraction, data transformation, statistical reporting and electronic publishing.
buyer: PRA International (PRAH:$1,698.48)
PRA International conducts clinical trials across all therapeutic areas in more than 80 countries and provides services in all phases of clinical development through its 40 global offices. "
target: Kinship Technologies Pvt. Ltd.
Kinship Technologies is a leading, global provider of innovative high-quality software products and services that enhance, optimize and accelerate the drug development process from source to submission through integration, automation and effective application of advanced technology solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/8/2017 via GlobeNewswire

PRA Health Sciences, will acquire Symphony Health Solutions

synopsis: PRA Health Sciences, Inc. (“PRA”), a leading clinical research organization, announced it has signed a definitive agreement to acquire Symphony Health Solutions Corporation (“Symphony Health”), a privately-held best-in-class provider of data, analytics and consulting solutions to the life sciences market.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: Symphony Technology Group
target: Symphony Health Solutions
Symphony Health Solutions is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth.
price ($mm)
$530
rev ($mm)
$200
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 3/18/2016 via BNC Analysis

PRA Health Sciences, acquired Nextrials, Inc.

synopsis: PRA Health Sciences acquired all of the outstanding shares of Nextrials, Inc., a developer of web-based software which integrates electronic health records with clinical trials. Nextrials is an innovative, award-winning, leader in web-based software solutions for the clinical research industry.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
At PRA Health Sciences, providing innovative solutions for their clients is what they do. They strive to move drug discovery forward, to help them develop life-saving and life- improving drugs. "
target: Nextrials, Inc.
Nextrials is an innovative, award-winning, leader in web-based software solutions for the clinical research industry. Prism®, the Company’s clinical trial management software, brings together sophisticated trial management and electronic data capture (“EDC”) in a single package.
price ($mm)
$4.70
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/20/2011 via PR Newswire

PRA International, acquired Kinship Technologies Pvt. Ltd.

synopsis: PRA International has acquired Kinship Technologies, a Chennai, India-based software developer and services company. Kinship's flagship product, EXACT, is a revolutionary system that allows users to quickly construct reusable programs for data extraction, data transformation, statistical reporting and electronic publishing.
buyer: PRA International (PRAH:$1,698.48)
PRA International conducts clinical trials across all therapeutic areas in more than 80 countries and provides services in all phases of clinical development through its 40 global offices. "
target: Kinship Technologies Pvt. Ltd.
Kinship Technologies is a leading, global provider of innovative high-quality software products and services that enhance, optimize and accelerate the drug development process from source to submission through integration, automation and effective application of advanced technology solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Kinship Technologies Pvt. Ltd.


read more

Kinship Technologies Pvt. Ltd.

Laiya Consulting, Inc.

Notocord

Logos Technologies

Conformia Software, Inc.

BSI Business Systems Integration

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

GoBalto

CRF Health

Sylogent

mProve Health

Parallel 6

ClinPlus

Bracket Global

SecureConsent

read more

Kinship Technologies Pvt. Ltd.

read more

Parallel 6

Symphony Health Solutions

Nextrials, Inc.

Kinship Technologies Pvt. Ltd.

read more

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Geography
Matching Companies
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2019
rev ($mm)
$30.83
EBITDA ($mm)
$4.12
EBIT ($mm)
$3.15
Net Income ($mm)
$2.27
Employees
238
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: OMCL
 
 
 
 
 
 
 
 
Omnicell, Inc.
Omnicell, Inc.
Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
year
2020
rev ($mm)
$906.40
EBITDA ($mm)
$100.91
EBIT ($mm)
$61.95
Net Income ($mm)
$49.09
Employees
2780
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: MRCY
 
 
 
 
 
 
 
 
Mercury Computer Systems, Inc.
Mercury Computer Systems, Inc.
Mercury Computer Systems is the leading supplier of high-performance digital signal and image processing systems. These embedded computer systems transform streams of sensor data to visual information in real time for analysis and interpretation.
year
2011
rev ($mm)
$228.71
EBITDA ($mm)
$33.90
EBIT ($mm)
$25.55
Net Income ($mm)
$18.44
Employees
602
  • drill down
  • watch
Ticker: SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc.
Scrypt, Inc.
Since 1998, Austin-based Scrypt, Inc. has been creating elegant document productivity tools for healthcare that eliminate manual processes and paper to save time and money. Scrypt has more than 30,000 customers across all 50 states.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.85)
EBIT ($mm)
($0.91)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: CERN
 
 
 
 
 
 
 
 
Cerner Corporation
Cerner Corporation
Cerner's health information technologies connect people, information, and systems. Cerner solutions assist clinicians in making care decisions and enable organizations to manage the health of populations.
year
2020
rev ($mm)
$5,714.46
EBITDA ($mm)
$1,168.86
EBIT ($mm)
$707.10
Net Income ($mm)
$510.39
Employees
27400
  • drill down
  • watch
Ticker: 300253
 
 
 
 
 
 
 
 
Shanghai Kingstar Winning Software Co., Ltd.
Shanghai Kingstar Winning Software is principally engaged in the development of medical software, the provision of technology services and the distribution of hardware products. They primarily offer software, including hospital information systems and public health information management systems.
year
2015
rev ($mm)
$98.42
EBITDA ($mm)
$14.01
EBIT ($mm)
$12.72
Net Income ($mm)
$21.57
Employees
454
  • drill down
  • watch
Ticker: OM:RTC
 
 
 
 
 
 
 
 
Rethinking Care AB
Rethinking Care AB
Rethinking Care introduces a holistic concept in nursing & health, based on 3 interacting spheres of activity - "Software as a service", "Care as a service" & "Health as a service", based on a high level of competence in nursing & healthcare services as well as IT tools developed for health care.
year
2016
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: INOV
 
 
 
 
 
 
 
 
Inovalon, Inc.
Inovalon, Inc.
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape.
year
2017
rev ($mm)
$449.36
EBITDA ($mm)
$75.91
EBIT ($mm)
$27.16
Net Income ($mm)
$34.82
Employees
2119
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch